https://www.selleckchem.com/pr....oducts/ci994-tacedin
Median clinical and biochemical disease activity remained stable after the switch. Median serum vedolizumab concentrations increased from 19 μg/ml at the time of the switch to 31 μg/ml 12 weeks after the switch (p 0.005). Switching from IV to SC vedolizumab maintenance treatment is effective in patients with CD or UC. However, 9% of patients were switched back to IV vedolizumab due to adverse events or fear of needles. Switching from IV to SC vedolizumab maintenance treatment is effective in patients with CD or UC. Howev
إعجاب
علق
شارك
